Legend Biotech’s Post

Thoughts on this? >> Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #biotech #pharma #healthcare

Thoughts on this? >> AACR: Regeneron’s multiple myeloma drug shows staying power, just after FDA accepts it for quick review >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #biotech #pharmaceutical #pharma

Thoughts on this? >> Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Yahoo Finance >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #pharma #biotech

Thoughts on this? >> Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #competitivemarketing #healthcare

🔹 According to GlobalData’s Pharmaceutical Intelligence Centre, there were 22,338 clinical trials initiated in #2023. The main indication of trials initiated in 2023 was oncology, followed by central nervous system. Of the trials initiated in 2023, the majority (36%) were Phase II trials. Also in 2023, 7,183 clinical trials ended, with 6,234 completing and 777 terminated. 🔹 #Oncology had the highest number of clinical trials in Phase I and II in 2023 while the central nervous system had the most Phase III and IV trials, the same as it was in 2022. 🔹 Although oncology had the highest number of trials within Phase I, #metabolic disorders had the largest proportion of Phase I trials with 36.5%, followed by cardiovascular (34.9%) and immunology (33.4%). #clinicaltrials #pharma #biotech #onlinecourses #SymmetricTraining

Roche Sequencing USA IL-6 Blocker Enspryng Faces Setback in Phase III Trial for Myasthenia Gravis 📉: 1. **Study Results**: Roche subsidiary Chugai Pharma Europe Pharmaceutical's Phase III LUMINESCE study revealed that Enspryng (satralizumab) could significantly improve symptoms of generalized myasthenia gravis (gMG), a chronic autoimmune disorder. However, the magnitude of the effects did not meet the company's expectations for clinical benefit. 🧐 2. **Safety Profile**: Enspryng was well-tolerated in the gMG study, with an adverse event profile consistent with previous trials in neuromyelitis optica spectrum disorder (NMOSD). Detailed results are set to be presented at the American Academy of Neurology Annual Meeting on April 15 in Denver, Colorado. 🛡️ 3. **Future Plans**: Despite this setback, Roche and Chugai plan to continue developing Enspryng for other inflammatory and neurological autoimmune conditions, including myelin oligodendrocyte glycoprotein-associated disorder, thyroid eye disease, and autoimmune encephalitis. This disappointing data contrasts with Roche's recent clinical successes, such as the positive Phase Ib/II study results for its Alzheimer's disease therapy trontinemab. 💡 For more details, check out the full article [here](https://lnkd.in/guFC-pAF).

📰 Novo Nordisk to buy Cardior Pharmaceuticals, targeting heart disease. The deal is estimated to be ~$1.1B. 🔬 Cardior's assets will be complementary and additive to their established CV/HF pipeline. The highlight of this deal, NN gets this unique MOA: "...an antisense oligonucleotide to inhibit a piece of non-coding RNA, miR-132, that is implicated in heart failure." Touted as 'first-in-class' potential, as it *may* reverse or halt the course of HF. #HeartFailure #HeartDisease #Cardiovascular #Pharma #Healthcare

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy: Get insights into ABPI's critical measures for sustaining the UK's life sciences industry ahead of Chancellor Jeremy Hunt's Budget announcement. Pricing & Reimbursement: Discover how Spain's Ministry of Health is granting unrestricted access to crucial treatments for spinal muscular atrophy (SMA), including Roche's Evrysdi and Biogen's Spinraza. HTA: Stay updated on the latest developments in HTA with insights into the European Commission's proposal for revised pharmaceutical legislation and its impact on scientific guidelines. Drug Approval: Explore the FDA's accelerated approval of Iovance Biotherapeutics' cell therapy, Amtagvi (lifileucel), for unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody. C&G Therapy: Learn about Novartis' Kymriah (tisagenlecleucel) receiving a rating indicating a hint of an "unquantifiable" benefit for treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and refractory or relapsed B-cell acute lymphoblastic leukemia (ALL). And more... READ NOW: https://ow.ly/uSgq50QHOgv

Thoughts on this? >> Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech